An announcement from Applied DNA Sciences ( (APDN) ) is now available.
On September 30, 2024, Applied DNA Sciences’ stockholders approved a reverse stock split to address non-compliance with Nasdaq’s minimum bid price requirements. Effective March 14, 2025, the 1-for-50 reverse stock split aims to reduce the number of outstanding shares from approximately 55.2 million to 1.1 million, helping the company regain compliance and maintain its Nasdaq listing.
More about Applied DNA Sciences
Applied DNA Sciences is a biotechnology company specializing in PCR-based DNA technologies. It operates in two main business markets: the enzymatic manufacture of synthetic DNA for nucleic acid-based therapeutics and the detection of DNA and RNA in molecular diagnostics and genetic testing services.
YTD Price Performance: -41.20%
Average Trading Volume: 4,117,710
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $8.11M
For a thorough assessment of APDN stock, go to TipRanks’ Stock Analysis page.